Black Rock Inc. Immuno Gen, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.46 - $29.95 $19.3 Million - $46.4 Million	1,550,533 Added 7.65%	21,824,392 $647 Million
Q3 2023 Nov 13, 2023	SELL	$14.09 - $19.87 $8.89 Million - $12.5 Million	-631,127 Reduced 3.02%	20,273,859 $322 Million
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $10.9 Million - $58.3 Million	2,908,657 Added 16.16%	20,904,986 $394 Million
Q1 2023 May 12, 2023	SELL	$3.67 - $4.92 $72,199 - $96,791	-19,673 Reduced 0.11%	17,996,329 $69.1 Million
Q4 2022 Feb 13, 2023	BUY	$4.55 - $6.31 $2.6 Million - $3.6 Million	570,976 Added 3.27%	18,016,002 $89.4 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $1.94 Million - $2.8 Million	-432,243 Reduced 2.42%	17,445,026 $83.4 Million
Q2 2022 Aug 12, 2022	BUY	$3.15 - $5.76 $4.55 Million - $8.32 Million	1,444,336 Added 8.79%	17,877,269 $80.4 Million
Q1 2022 May 12, 2022	BUY	$4.26 - $7.48 $6.69 Million - $11.7 Million	1,569,629 Added 10.56%	16,432,933 $78.2 Million
Q4 2021 Feb 10, 2022	SELL	$4.75 - $7.5 $2.46 Million - $3.89 Million	-518,571 Reduced 3.37%	14,863,304 $110 Million
Q3 2021 Nov 09, 2021	SELL	$5.02 - $6.59 $173,546 - $227,822	-34,571 Reduced 0.22%	15,381,875 $87.2 Million
Q2 2021 Aug 11, 2021	BUY	$5.79 - $8.6 $89.3 Million - $133 Million	15,416,446 New	15,416,446 $102 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.